SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 in Losses from Investment in Sanofi to Contact

  SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000
  in Losses from Investment in Sanofi to Contact Brower Piven Before the
  February 10, 2014 Lead Plaintiff Deadline

Business Wire

STEVENSON, Md. -- January 6, 2014

Brower Piven, A Professional Corporation announces that a class action lawsuit
has been commenced in the United States District Court for the Southern
District of New York on behalf of purchasers of Sanofi (“Sanofi” or the
“Company”) (NasdaqGM: GCVRZ) contingent value rights (“CVRs”) during the
period between March 6, 2012 and November 7, 2013, inclusive (the “Class

If you have suffered a net loss from investment in Sanofi CVRs purchased on or
after March 6, 2012, and held through the revelation of negative information
on November 8, 2013, as described below, at no cost to you, you may obtain
additional information about this lawsuit and your ability to become a lead
plaintiff by contacting Brower Piven at, by email at, by calling 410/415-6616, or at Brower Piven, A
Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153.
Attorneys at Brower Piven have combined experience litigating securities and
class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will
be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply
to be appointed lead plaintiff no later than February 10, 2014 and be selected
by the Court. The lead plaintiff will direct the litigation and participate in
important decisions including whether to accept a settlement and how much of a
settlement to accept for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from investment in
the Company during the Class Period.

The complaint accuses the defendants of violations of the Securities Exchange
Act of 1934 by virtue of the defendants’ failure to disclose during the Class
Period that the Company’s 323 and 324 trials for Lemtrada, a treatment for
multiple sclerosis, contained high levels of placebo effect and observer bias
which tainted the results and thereby lowered the likelihood of Lemtrada being
approved by the U.S. Food and Drug Administration (“FDA”). According to the
complaint, following the issuance of a November 8, 2013 briefing report by the
FDA Advisory Committee on Peripheral and Central Nervous System Drugs, which
criticized the Company’s submission to the FDA and expressed significant
concerns regarding the safety profile of Lemtrada and the adequacy of the
efficacy data, the value of Sanofi CVRs declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial
obligation or cost to you, or you may retain other counsel of your choice. You
need take no action at this time to be a member of the class.


Brower Piven, A Professional Corporation
Stevenson, Maryland
Charles J. Piven, 410-415-6616
Press spacebar to pause and continue. Press esc to stop.